2nd Quarter - Report

INFUSION PROVIDERS ALLIANCE for INFUSION PROVIDERS ALLIANCE

Firm
Client
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act

LobbyistCovered position, as disclosed
ELLIOTT WARREN New —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); SENATE

Bills named: H.R. 4299 (119th), H.R. 879 (119th)

Health Issues HCR

Advocating for access to and reimbursement for biosimilars. Issues related to patient access to infusion products for asthma and allergies.

LobbyistCovered position, as disclosed
ELLIOTT WARREN New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.